Applications close in 7 days
£120,000 - £150,000 / year
Following the signing of their 2nd major pharma collaboration of 2020, and 3rd to date since their inception just 4 years ago, and due to the first-and-leading-mover status within its next-generation technology space; this already well funded and highly anticipated Cell & Gene Therapy Biotech, led by arguably the most prestigious innovators in their scientific discipline and that has experienced >100% growth through further obtainment of best-in-industry professionals since March, now has a new leadership opportunity for an achieved Director/Senior Director CMC – Cell & Gene Therapy, to join them on this next major trajectory of expansion as they accelerate towards manufacturing and first-in-man clinical trials.
This position would only be suitable for someone with a genuine aspiration for, and work ethos towards a significantly accelerated career opportunity within a high-profile, rapidly transforming and assertively advancing start up Biotech environment, exposed to ever evolving accomplishments of next-generation technology innovations within the Cell & Gene Therapy space, such as the ability to reach previously inaccesible tissues.
With more patent filings and grants than any other player in their space, including within their CMC process; the Director of CMC will play a key and critical role in the CMC Leadership team, as well as broader and longer term company strategy, by enabling FIM, late stage clinical trials and commercialisation of both internal and partnered product and platform technology programs.
Therefore, as well as significant upstream process development and cell line development experience, this person will have a demonstrable track record of successful leadership in delivering CMC projects within cell & gene therapy. This person will be required to add to the already highly desirable and often primary draw that is their unified, visionary internal culture, set from the extremely popular CEO down, who to date has handwritten letters of thanks to over 50 of the workforce and awarded unannounced and equal financial bonuses (regardless of function, seniority of length of service) to every member of the business upon signing partnership deals as a token of his appreciation for their efforts.
Due to the combined attractiveness of the technology, employee calibre and culture, we are already receiving interest from Next Phase’s direct cell & gene therapy portfolio. Therefore if this has raised intrigue and you feel you have the key criteria to be considered (upstream process development, cell line development and leadership), it is strongly advised to apply without hesitation to avoid disappointment.
Best of luck